Adents Prodigi provides unit identification and traceability, OEE and productivity monitoring across production sites, as well as real-time data visualization and analysis.
The demand for unique product identification solutions is driven by a global increase in regulations for the pharmaceutical industry. More than 80% of global drug production will need to be compliant with regulations regarding unit identification by 2019. This new process offers opportunities in terms of visibility on the life of products, but also represents a major challenge in terms of data management.
Adents Prodigi utilizes Microsoft Azure technologies and allows drug manufacturers to securely generate, exchange and control the large amount of data created through unit identification. The Adents Prodigi platform also integrates data analysis (including Microsoft Power BI) and machine learning tools, providing analytics capabilities for these new sources of information.
Adents Prodigi was developed collaboratively by a team of Adents and Microsoft experts, and can host business applications offered by third parties to exploit data stored on the platform.
“Our alliance with the leader of Business Intelligence will be a game changer on the global market for unit identification. Indeed, this will finally give the pharmaceutical industry the means to tap into the full potential of the wealth of information generated through serialization,” said Christophe Devins, founder and chief executive officer of Adents.